Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01462435
Other study ID # DIC3-08-04
Secondary ID
Status Completed
Phase Phase 3
First received October 26, 2011
Last updated January 2, 2014
Start date October 2011
Est. completion date August 2012

Study information

Verified date January 2014
Source Iroko Pharmaceuticals, LLC
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether Diclofenac [Test] Capsules are safe and effective for the treatment of bunionectomy pain.


Recruitment information / eligibility

Status Completed
Enrollment 428
Est. completion date August 2012
Est. primary completion date February 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Patient is male or female between 18 and 65 years of age

- For women of child-bearing potential: a woman who is not pregnant and not nursing, and who is practicing an acceptable method of birth control

- Has undergone primary, unilateral, first metatarsal bunionectomy with no additional collateral procedures

- Patient must be willing to stay at the study site = 72 hours

Exclusion Criteria:

- Patient has hypersensitivity, allergy, or clinically significant intolerance to any medications to be used in the study, or related drugs

- Patient has a current disease or history of a disease that will impact the study or the patient's well-being

- Patient has used or intends to use any of the medications that are prohibited by the protocol

- Patient has a history of drug or alcohol abuse or dependence, or patient has a positive urine drug screen or alcohol breathalyzer test

- Patient has taken another investigational drug within 30 days prior to screening

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Diclofenac Test (lower dose)
Capsules
Diclofenac Test (upper dose)
Capsules
Celecoxib
200 mg Capsules
Placebo
Capsules

Locations

Country Name City State
United States Premier Research Group Limited Austin Texas
United States Chesapeake Research Group, LLC Pasadena Maryland
United States Premier Research Group Limited Phoenix Arizona
United States Premier Research Group Limited Salt Lake City Utah

Sponsors (1)

Lead Sponsor Collaborator
Iroko Pharmaceuticals, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Time-Weighted Summed Pain Intensity Difference Measured Using the 100-mm Visual Analogue Scale From 0 to 48 Hours After Trial Entry (VASSPID-48), ANCOVA Model. The pain intensity is assessed using a visual analogue scale (VAS), which is a horizontal line 100 mm in length. Subjects mark the VAS with a single vertical line to indicate their current pain level, with 0 mm representing "No Pain" and 100 mm representing "Worst Possible Pain".
The VAS summed pain intensity difference (VASSPID) is calculated as the sum of the pain intensity difference values at each follow-up time point (difference between the starting pain intensity and the pain intensity at the given assessment time) multiplied by the amount of time (in hours) since the prior assessment.
0 - 48 hours No
Secondary VASSPID-4. The Time-Weighted Summed Pain Intensity Difference Measured Using the 100-mm Visual Analogue Scale (VASSPID) From 0 to 4 Hours After Trial Entry. The pain intensity is assessed using a visual analogue scale (VAS), which is a horizontal line 100 mm in length. Subjects mark the VAS with a single vertical line to indicate their current pain level, with 0 mm representing "No Pain" and 100 mm representing "Worst Possible Pain".
The VAS summed pain intensity difference (VASSPID) is calculated as the sum of the pain intensity difference values at each follow-up time point (difference between the starting pain intensity and the pain intensity at the given assessment time) multiplied by the amount of time (in hours) since the prior assessment.
0 - 4 hours No
Secondary VASSPID-8. The Time-Weighted Summed Pain Intensity Difference Measured Using the 100-mm Visual Analogue Scale (VASSPID) From 0 to 8 Hours After Trial Entry. The pain intensity is assessed using a visual analogue scale (VAS), which is a horizontal line 100 mm in length. Subjects mark the VAS with a single vertical line to indicate their current pain level, with 0 mm representing "No Pain" and 100 mm representing "Worst Possible Pain".
The VAS summed pain intensity difference (VASSPID) is calculated as the sum of the pain intensity difference values at each follow-up time point (difference between the starting pain intensity and the pain intensity at the given assessment time) multiplied by the amount of time (in hours) since the prior assessment.
0 - 8 hours No
Secondary VASSPID-24. The Time-Weighted Summed Pain Intensity Difference Measured Using the 100-mm Visual Analogue Scale (VASSPID) From 0 to 24 Hours After Trial Entry. The pain intensity is assessed using a visual analogue scale (VAS), which is a horizontal line 100 mm in length. Subjects mark the VAS with a single vertical line to indicate their current pain level, with 0 mm representing "No Pain" and 100 mm representing "Worst Possible Pain".
The VAS summed pain intensity difference (VASSPID) is calculated as the sum of the pain intensity difference values at each follow-up time point (difference between the starting pain intensity and the pain intensity at the given assessment time) multiplied by the amount of time (in hours) since the prior assessment.
0 - 24 hours No
Secondary Total Pain Relief (TOTPAR) Over 0 to 4 Hours. TOTPAR-4. Pain relief was assessed using a 5-point categorical scale at all assessment time points after time 0. Subjects were asked "How much relief have you had since your starting pain?" with response choices of none = 0, a little = 1, some = 2, a lot = 3, and complete = 4.
The Total Pain Relief (TOTPAR) score for a given time interval is calculated as the sum of the pain relief scores at each follow-up time point (as recorded on the categorical pain relief scale) over that interval multiplied by the amount of time (in hours) since the prior assessment. In this way individual scores covering a longer time period were given more weight.The minimum theoretical score is 0 units, which represent no relief from pain (score of 0 on categorical scale) at all time points after time 0. The maximum theoretical score is 16 units, which represents complete relief from pain (score of 4 on a categorical scale) at all time points after time 0.
0 - 4 hours No
Secondary TOTPAR-8. Total Pain Relief (TOTPAR) Over 0 to 8 Hours Pain relief was assessed using a 5-point categorical scale at all assessment time points after time 0. Subjects were asked "How much relief have you had since your starting pain?" with response choices of none = 0, a little = 1, some = 2, a lot = 3, and complete = 4.
The Total Pain Relief (TOTPAR) score for a given time interval is calculated as the sum of the pain relief scores at each follow-up time point (as recorded on the categorical pain relief scale) over that interval multiplied by the amount of time (in hours) since the prior assessment. In this way individual scores covering a longer time period were given more weight. The minimum theoretical score is 0 units, which represent no relief from pain (score of 0 on categorical scale) at all time points after time 0. The maximum theoretical score is 32 units, which represents complete relief from pain (score of 4 on a categorical scale) at all time points after time 0.
0 - 8 hours No
Secondary TOTPAR-24. Total Pain Relief (TOTPAR) Over 0 to 24 Hours Pain relief was assessed using a 5-point categorical scale at all assessment time points after time 0. Subjects were asked "How much relief have you had since your starting pain?" with response choices of none = 0, a little = 1, some = 2, a lot = 3, and complete = 4.
The Total Pain Relief (TOTPAR) score for a given time interval is calculated as the sum of the pain relief scores at each follow-up time point (as recorded on the categorical pain relief scale) over that interval multiplied by the amount of time (in hours) since the prior assessment. In this way individual scores covering a longer time period were given more weight. The minimum theoretical score is 0 units, which represent no relief from pain (score of 0 on categorical scale) at all time points after time 0. The maximum theoretical score is 96 units, which represents complete relief from pain (score of 4 on a categorical scale) at all time points after time 0.
0 - 24 hours No
Secondary TOTPAR-48. Total Pain Relief (TOTPAR) Over 0 to 48 Hours Pain relief was assessed using a 5-point categorical scale at all assessment time points after time 0. Subjects were asked "How much relief have you had since your starting pain?" with response choices of none = 0, a little = 1, some = 2, a lot = 3, and complete = 4.
The Total Pain Relief (TOTPAR) score for a given time interval is calculated as the sum of the pain relief scores at each follow-up time point (as recorded on the categorical pain relief scale) over that interval multiplied by the amount of time (in hours) since the prior assessment. In this way individual scores covering a longer time period were given more weight. The minimum theoretical score is 0 units, which represent no relief from pain (score of 0 on categorical scale) at all time points after time 0. The maximum theoretical score is 192 units, which represents complete relief from pain (score of 4 on a categorical scale) at all time points after time 0.
0 - 48 hours No
See also
  Status Clinical Trial Phase
Terminated NCT02801799 - Effects of Local Anaesthetic Infusion Rates on Nerve Block Duration Phase 1
Withdrawn NCT01324544 - Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Who Require Opioid Analgesia for Acute Moderate to Severe Pain Phase 3
Completed NCT01626118 - Study of Indomethacin Capsules to Treat Pain Following Bunionectomy Phase 3
Completed NCT01304134 - Oxycodone Hydrochloride Injection in the Postoperative Pain Relieving Treatment Phase 3
Terminated NCT02161484 - Continuous Lumbar Plexus Block With and Without Parasacral Block in Patients Undergoing Total Hip Replacement N/A
Recruiting NCT02645474 - Is PECS Block Equivalent to Paravertebral Block in Preventing Postoperative Pain After Breast Surgery? Phase 4
Completed NCT01543685 - Study of Indomethacin Capsules to Treat Pain Following Bunionectomy Phase 3
Completed NCT01858402 - Paracetamol Versus Dipyrone After Pediatric Lower Abdominal Surgery in Children With Spinal Anesthesia Phase 2
Completed NCT01322074 - Systemic Inflammation Versus Acute Pain in Total Knee Arthroplasty (TKA) N/A